There are 2789 resources available
737P - Phase II study of IV vinorelbine in relapsed platinum resistant or refractory C5 high grade serous primary peritoneal, fallopian tube or ovarian cancer (VIP)
Presenter: Natalie Ngoi
Session: ePoster Display
688P - Gene expression profiling (GEP) signatures associated with markers of sensitivity to immune and angiogenic therapy in clear-cell renal cell carcinoma (ccRCC) with sarcomatoid/rhabdoid features
Presenter: Pedro Miguel Coelho Barata
Session: ePoster Display
689P - Human leukocyte antigen (HLA) class I/II expression as a predictive biomarker for response to immune oncology (IO) therapy in metastatic clear-cell renal cell carcinoma (m-ccRCC)
Presenter: Lisa Kinget
Session: ePoster Display
690P - Comprehensive genomic profiling (CGP) of VHL mutated and VHL wild type clear cell renal cell carcinoma (ccRCC)
Presenter: Gennady Bratslavsky
Session: ePoster Display
691P - Effect of NANOGNB mutations on DNA damage response and efficacy of immune checkpoint inhibitors in advanced renal clear cell carcinoma
Presenter: Zhiwen Luo
Session: ePoster Display
Resources:
Abstract
692P - Characterization of the tumor immune microenvironment in early-stage clear cell renal cell carcinoma (ccRCC): Prognostic value of an M0-macrophage enriched subtype
Presenter: Mark Farha
Session: ePoster Display
693P - Plasma exosome microRNA-155-3p expression in patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors: Potential biomarker of response to systemic therapy
Presenter: Maryam Soleimani
Session: ePoster Display
694P - Methylthioadenosine phosphorylase (MTAP) deletion is more common in sarcomatoid (srcRCC) than in clear cell renal cell carcinoma (ccRCC)
Presenter: Andrea Necchi
Session: ePoster Display
695P - Drug-drug interactions between pazopanib and proton pump inhibitors may significantly affect clinical outcome of patients affected by metastatic renal cell carcinoma
Presenter: Marzia Del Re
Session: ePoster Display
696P - Is it possible to improve the prognostic ability of the IMDC score? Validation of the Meet-URO score in metastatic renal cell carcinoma (mRCC) patients (pts) receiving first-line nivolumab plus ipilimumab in the Italian Expanded Access Program (EAP)
Presenter: Sara Elena Rebuzzi
Session: ePoster Display